University of London Institute in Paris

The stability of carbon-supported electrocatalysts has been largely investigated in acidic electrolytes, but the literature is much scarcer regarding similar stability studies in alkaline medium. Herein, the degradation of Vulcan XC-72-supported platinum nanoparticles (noted Pt/C), a state-of-the-art proton exchange membrane fuel cell electrocatalyst, is investigated in alkaline medium by combining electrochemical measurements and identical location transmission electron microscopy; electrochemical surface area (ECSA) losses were bridged to electrocatalyst morphological changes. The results demonstrate that the degradation in 0.1 M NaOH at 25 °C is severe (60% of ECSA loss after only 150 cycles between 0.1 and 1.23 V vs RHE), which is about 3 times worse than in acidic media for this soft accelerated stress test. Severe carbon corrosion has been ruled out according to Raman spectroscopy and X-ray photoelectron spectroscopy measurements, and it seems that the chemistry of the carbon support (in particular, the interface (chemical bounding)) between the Pt nanoparticles and their carbon substrate does play a significant role in the observed degradations.

High-income cities face significant challenges in mitigating anthropogenic climate change; constraints exist in their evolution towards low-carbon urban systems due to their mature infrastructure, established energy sources and recent uncertainty in economic growth.The extent of these challenges depends on individual economic, social and environmental contexts.Seto et al. (2014) present four principal drivers of urban emissions in the Intergovernmental Panel on Climate Change's Fifth Assessment Report: economic geography & income, socio-demographic factors, technology and infrastructure & urban form.Given that these drivers vary substantially across urban areas in highincome cities, emissions per capita also differ (see Figure 1).However, regardless of context, deep emissions reductions in these cities are necessary.High-income cities are principal drivers of energy consumption within their national boundaries.Grubler et al. ( 2012) estimate that over 80% of energy use in OECD90 1 countries took place in their urban areas in 2005.Moreover, Elzen et al. ( 2013) calculate that industrialized nations have contributed 52% of all emissions between 1850-2010, while having only hosted 26.7% of the global population during that time.These industrialized countries have undergone rapid urbanization in the past 60 years, with the United Nations (UN) (2014) suggesting that populations living in cities increased from 54.6% to 77.1% between 1950 and 2010.Cities in industrialized nations also enable much of the world's economic activity, with 380 high-income cities contributed to 50% of GDP in 2007 (Mckinsey Global Institute, 2011); GDP per capita has been shown to be correlate with GHG emissions (Kennedy, 2014).When considering energy demand, history of GHG emissions, high levels of urbanization and large economies, a case can be made that high-income cities are substantial contributors to climate change, supporting the call for their leadership towards a low-carbon future.1 OECD90 includes countries in OECD Asia, Western Europe and North America

The electrochemical oxidation of carbon is a pivotal problem for low-temperature electrochemical generators, among which are proton-exchange membrane fuel cells (PEMFCs), and (non)aqueous-electrolyte Li–air batteries. In this contribution, the structure-sensitivity of the electrochemical corrosion of high-surface area carbon (HSAC) used to support catalytic materials in PEMFC electrodes is investigated in model (liquid electrolyte, 96 h potentiostatic holds at different electrode potentials ranging from 0.40 to 1.40 V at T = 330 K) and real PEMFC operating conditions (solid polymer electrolyte, 12,860 h of operation at constant current). Characterizations from Raman spectroscopy demonstrate that the disordered domains of HSAC supports (amorphous carbon and defective graphite crystallites) are preferentially oxidized at voltages related to the PEMFC cathode (0.40 < E < 1.00 V). Excursions to high electrode potential E > 1.00 V, witnessed during start-up and shut-down of PEMFC systems, accelerate this phenomenon and propagate the electrochemical oxidation to the graphitic domains of the HSAC. Thanks to X-ray photoelectron spectroscopy, a better understanding of the relationships existing between structural changes and carbon surface oxides coverage is also emerging for the first time.

One of the most critical tasks for improving data quality and increasing the reliability of data analytics is Entity Resolution (ER), which aims to identify different descriptions that refer to the same real-world entity. Despite several decades of research, ER remains a challenging problem. In this survey, we highlight the novel aspects of resolving Big Data entities when we should satisfy more than one of the Big Data characteristics simultaneously (i.e., Volume and Velocity with Variety). We present the basic concepts, processing steps, and execution strategies that have been proposed by database, semantic Web, and machine learning communities in order to cope with the loose structuredness , extreme diversity , high speed, and large scale of entity descriptions used by real-world applications. We provide an end-to-end view of ER workflows for Big Data, critically review the pros and cons of existing methods, and conclude with the main open research directions.

Throughout the day, cognitive performance is under the combined influence of circadian processes and homeostatic sleep pressure. Some people perform best in the morning, whereas others are more alert in the evening. These chronotypes provide a unique way to study the effects of sleep-wake regulation on the cerebral mechanisms supporting cognition. Using functional magnetic resonance imaging in extreme chronotypes, we found that maintaining attention in the evening was associated with higher activity in evening than morning chronotypes in a region of the locus coeruleus and in a suprachiasmatic area (SCA) including the circadian master clock. Activity in the SCA decreased with increasing homeostatic sleep pressure. This result shows the direct influence of the homeostatic and circadian interaction on the neural activity underpinning human behavior.

Patients with Wiskott-Aldrich syndrome (WAS) lacking a human leukocyte antigen-matched donor may benefit from gene therapy through the provision of gene-corrected, autologous hematopoietic stem/progenitor cells. Here, we present comprehensive, long-term follow-up results (median follow-up, 7.6 years) (phase I/II trial no. NCT02333760 ) for eight patients with WAS having undergone phase I/II lentiviral vector-based gene therapy trials (nos. NCT01347346 and NCT01347242 ), with a focus on thrombocytopenia and autoimmunity. Primary outcomes of the long-term study were to establish clinical and biological safety, efficacy and tolerability by evaluating the incidence and type of serious adverse events and clinical status and biological parameters including lentiviral genomic integration sites in different cell subpopulations from 3 years to 15 years after gene therapy. Secondary outcomes included monitoring the need for additional treatment and T cell repertoire diversity. An interim analysis shows that the study meets the primary outcome criteria tested given that the gene-corrected cells engrafted stably, and no serious treatment-associated adverse events occurred. Overall, severe infections and eczema resolved. Autoimmune disorders and bleeding episodes were significantly less frequent, despite only partial correction of the platelet compartment. The results suggest that lentiviral gene therapy provides sustained clinical benefits for patients with WAS.

The use of artificial intelligence (AI) in a variety of research fields is speeding up multiple digital revolutions, from shifting paradigms in healthcare, precision medicine and wearable sensing, to public services and education offered to the masses around the world, to future cities made optimally efficient by autonomous driving. When a revolution happens, the consequences are not obvious straight away, and to date, there is no uniformly adapted framework to guide AI research to ensure a sustainable societal transition. To answer this need, here we analyze three key challenges to interdisciplinary AI research, and deliver three broad conclusions: 1) future development of AI should not only impact other scientific domains but should also take inspiration and benefit from other fields of science, 2) AI research must be accompanied by decision explainability, dataset bias transparency as well as development of evaluation methodologies and creation of regulatory agencies to ensure responsibility, and 3) AI education should receive more attention, efforts and innovation from the educational and scientific communities. Our analysis is of interest not only to AI practitioners but also to other researchers and the general public as it offers ways to guide the emerging collaborations and interactions toward the most fruitful outcomes.

Chronic graft-versus-host disease (cGvHD) is a severe complication of allogeneic hematopoietic stem cell transplantation that affects various organs leading to a reduced quality of life. The condition often requires enduring immunosuppressive therapy, which can also lead to the development of severe side effects. Several approaches including small molecule inhibitors, antibodies, cytokines, and cellular therapies are now being developed for the treatment of cGvHD, and some of these therapies have been or are currently tested in clinical trials. In this review, we discuss these emerging therapies with particular emphasis on tyrosine kinase inhibitors (TKIs). TKIs are a class of compounds that inhibits tyrosine kinases, thereby preventing the dissemination of growth signals and activation of key cellular proteins that are involved in cell growth and division. Because they have been shown to inhibit key kinases in both B cells and T cells that are involved in the pathophysiology of cGvHD, TKIs present new promising therapeutic approaches. Ibrutinib, a Bruton tyrosine kinase (Btk) inhibitor, has recently been approved by the Food and Drug Administration (FDA) in the United States for the treatment of adult patients with cGvHD after failure of first-line of systemic therapy. Also, Janus Associated Kinases (JAK1 and JAK2) inhibitors, such as itacitinib (JAK1) and ruxolitinib (JAK1 and 2), are promising in the treatment of cGvHD. Herein, we present the current status and future directions of the use of these new drugs with particular spotlight on their targeting of specific intracellular signal transduction cascades important for cGvHD, in order to shed some light on their possible mode of actions.

Abstract It is usually believed that carbon‐supported electrocatalysts are stable in alkaline environment, owing to the better thermodynamics stability of many metals and oxides at high pH. By focusing on a selected literature review concerning Pt/C and Pd/C nanoparticles, and in particular from identical‐location transmission electron microscopy (ILTEM), it is demonstrated that this “common knowledge” is erroneous in aqueous alkaline electrolytes: both Pt/C and Pd/C suffer pronounced loss of electrochemical surface area (ECSA), and the latter is linked to the detachment of the metal nanoparticles from the carbon support. Raman and X‐ray photoelectron spectroscopy show that these severe degradations are neither linked to massive corrosion of the carbon support nor to an overall change in carbon chemistry, but instead to a very localized corrosion of the carbon in the vicinity of the metal nanoparticles, leading to nucleation and growth of solid carbonate (when the electrolyte contains alkali metal cations), which expels the metal nanoparticles from their support. The mechanisms and extent of degradation depend on the nature of the metal nanoparticles, but also on their texture and on the nature of the support onto which they are immobilized.

Abstract The 2015 Paris agreement represents a deep-rooted change in global climate governance. While existing scholarly assessments highlight central institutional features of the Paris shift, they tend to overlook its symbolic and discursive dimensions. Our analysis shows that the Paris architecture combines two core elements: an iterative pledge and review process to stimulate global climate action, and a ‘performative’ narrative aimed at aligning actors’ expectations on the prospect of a low-carbon future. We therefore suggest calling it an incantatory system of governance. We then examine the origins of the new approach and find that the rise of ‘soft law’ approaches and communicative techniques in global climate governance are both indicative of a broader process: the entry of management culture in international organisations. Against this backdrop, we examine the prospects, limitations and caveats of the new approach and discuss its wider implications for global politics.

The role of ribosome biogenesis in erythroid development is supported by the recognition of erythroid defects in ribosomopathies in both Diamond-Blackfan anemia and 5q- syndrome. Whether ribosome biogenesis exerts a regulatory function on normal erythroid development is still unknown. In the present study, a detailed characterization of ribosome biogenesis dynamics during human and murine erythropoiesis showed that ribosome biogenesis is abruptly interrupted by the decline in ribosomal DNA transcription and the collapse of ribosomal protein neosynthesis. Its premature arrest by the RNA Pol I inhibitor CX-5461 targeted the proliferation of immature erythroblasts. p53 was activated spontaneously or in response to CX-5461, concomitant to ribosome biogenesis arrest, and drove a transcriptional program in which genes involved in cell cycle-arrested, negative regulation of apoptosis, and DNA damage response were upregulated. RNA Pol I transcriptional stress resulted in nucleolar disruption and activation of the ATR-CHK1-p53 pathway. Our results imply that the timing of ribosome biogenesis extinction and p53 activation is crucial for erythroid development. In ribosomopathies in which ribosome availability is altered by unbalanced production of ribosomal proteins, the threshold downregulation of ribosome biogenesis could be prematurely reached and, together with pathological p53 activation, prevents a normal expansion of erythroid progenitors.

Intestinal tissue-resident memory CD8 T cells (Trm) are non-recirculating effector cells ideally positioned to detect and react to microbial infections in the gut mucosa. There is an emerging understanding of Trm cell differentiation and functions, but their implication in inflammatory bowel diseases, such as Crohn's disease (CD), is still unknown. Here, we describe CD8 cells in the human intestine expressing KLRG1 or CD103, two receptors of E-cadherin. While CD103 CD8 T cells are present in high numbers in the mucosa of CD patients and controls, KLRG1 CD8 T cells are increased in inflammatory conditions. Mucosal CD103 CD8 T cells are more responsive to TCR restimulation, but KLRG1 CD8 T cells show increased cytotoxic and proliferative potential. CD103 CD8 T cells originate mostly from KLRG1 negative cells after TCR triggering and TGFβ stimulation. Interestingly, mucosal CD103 CD8 T cells from CD patients display major changes in their transcriptomic landscape compared to controls. They express Th17 related genes including CCL20, IL22, and IL26, which could contribute to the pathogenesis of CD. Overall, these findings suggest that CD103 CD8 T cells in CD induce a tissue-wide alert increasing innate immune responses and recruitment of effector cells such as KLRG1 CD8 T cells.

International audience

The clinical significance of the BRAF V600E mutation in adult Langerhans cell histiocytosis (LCH), including pulmonary Langerhans cell histiocytosis (PLCH), is not well understood. Similarly, the spectrum of molecular alterations involved in adult LCH has not been fully delineated. To address these issues, we genotyped a large number of adult LCH biopsies and searched for an association of identified molecular alterations with clinical presentation and disease outcome. Biopsies from 117 adult LCH patients, 83 with PLCH (median age 36.4 years, 56 females, 38 multisystem disease, 79 single system disease, 65 current smokers) were genotyped for the BRAF V600E mutation. In 69 cases, LCH lesions were also genotyped by whole-exome sequencing (WES) or targeted gene panel next-generation sequencing (NGS). Cox models were used to estimate the association of baseline characteristics with the hazard of LCH progression. MAPK pathway alterations were detected in 59 out of 69 cases (86%) ( BRAF V600E mutation: 36%, BRAF N486_P490 deletion: 28%, MAP2K1 mutations: 15%, isolated NRAS Q61 mutations: 4%), while KRAS mutations were virtually absent in PLCH lesions. The BRAF V600E mutation was not associated with LCH presentation at diagnosis, including smoking status and lung function, in PLCH patients. BRAF V600E status did not influence the risk of LCH progression over time. Thus, MAPK alterations are present in most lesions from adult LCH patients, particularly in PLCH. Unlike reports in paediatric LCH, BRAF V600E genotyping did not provide additional information on disease outcome. The search for alterations involved in the MAPK pathway, including BRAF deletions, is useful for guiding targeted treatment in selected patients with refractory progressive LCH.

Measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy is predictive of early relapse and poor survival. Postremission maintenance therapy that prolongs MRD negativity or converts MRD+ patients to MRD- status may delay or prevent relapse and improve overall survival (OS). In the phase 3 QUAZAR AML-001 trial, oral azacitidine (oral-AZA; formerly CC-486), a hypomethylating agent, significantly prolonged OS and relapse-free survival (RFS) compared with placebo in patients aged ≥55 years with AML in first remission after intensive chemotherapy who were not candidates for hematopoietic stem cell transplantation. In this trial, MRD (≥0.1% leukemic cells in bone marrow) was assessed by multiparameter flow cytometry in serial samples collected at baseline and on day 1 of every 3 cycles. As expected, baseline MRD status was significantly associated with both OS and RFS. Multivariate analyses showed oral-AZA significantly improved OS and RFS vs placebo independent of baseline MRD status. Oral-AZA treatment also extended the duration of MRD negativity by 6 months vs placebo and resulted in a higher rate of conversion from MRD+ at baseline to MRD- during treatment: 37% vs 19%, respectively. In the oral-AZA arm, 24% of MRD responders achieved MRD negativity >6 months after treatment initiation. Although presence or absence of MRD was a strong prognostic indicator of OS and RFS, there were added survival benefits with oral-AZA maintenance therapy compared with placebo, independent of patients' MRD status at baseline. Registered at clinicaltrials.gov as #NCT01757535.

In patients with isocitrate dehydrogenase (IDH)-mutated acute myeloid leukemia (AML) treated by intensive chemotherapy (IC), prognostic significance of co-occurring genetic alterations and allogeneic hematopoietic stem cell transplantation (HSCT) are of particular interest with the advent of IDH1/2 mutant inhibitors. We retrospectively analyzed 319 patients with newly diagnosed AML (127 with IDH1, 135 with IDH2R140, and 57 with IDH2R172 mutations) treated with IC in 3 Acute Leukemia French Association prospective trials. In each IDH subgroup, we analyzed the prognostic impact of clinical and genetic covariates, and the role of HSCT. In patients with IDH1 mutations, the presence of NPM1 mutations was the only variable predicting improved overall survival (OS) in multivariate analysis (P < .0001). In IDH2R140-mutated AML, normal karyotype (P = .008) and NPM1 mutations (P = .01) predicted better OS. NPM1 mutations were associated with better disease-free survival (DFS; P = .0009), whereas the presence of DNMT3A mutations was associated with shorter DFS (P = .0006). In IDH2R172-mutated AML, platelet count was the only variable retained in the multivariate model for OS (P = .002). Among nonfavorable European LeukemiaNet 2010-eligible patients, 71 (36%) underwent HSCT in first complete remission (CR1) and had longer OS (P = .03) and DFS (P = .02) than nontransplanted patients. Future clinical trials testing frontline IDH inhibitors combined with IC may consider stratification on NPM1 mutational status, the primary prognostic factor in IDH1- or IDH2R140-mutated AML. HSCT improve OS of nonfavorable IDH1/2-mutated AML and should be fully integrated into the treatment strategy.

Pediatric cancers, particularly high-risk solid tumors, urgently need effective and specific therapies. Their outlook has not appreciably improved in decades. Immunotherapies such as immune checkpoint inhibitors offer much promise, but most are only approved for use in adults. Though several hundred clinical trials have tested immune-based approaches in childhood cancers, few have been guided by biomarkers or clinical-grade assays developed to predict patient response and, ultimately, to help select those most likely to benefit. There is extensive evidence in adults to show that immune profiling has substantial predictive value, but few studies focus on childhood tumors, because of the relatively small disease population and restricted use of immune-based therapies. For instance, only one published study has retrospectively examined the immune profiles of pediatric brain tumors after immunotherapy. Furthermore, application and integration of advanced multiplex techniques has been extremely limited. Here, we review the current status of immune profiling of pediatric solid tumors, with emphasis on tumor types that represent enormous unmet clinical need, primarily in the context of immune checkpoint inhibitor therapy. Translating optimized and informative immune profiling into standard practice and access to personalized combination therapy will be critical if childhood cancers are to be treated effectively and affordably.

Most acute promyelocytic leukemia (APL) are caused by PML-RARA, a translocation-driven fusion oncoprotein discovered three decades ago. Over the years, several other types of rare X-RARA fusions have been described, while recently, oncogenic fusion proteins involving other retinoic acid receptors (RARB or RARG) have been associated to very rare cases of acute promyelocytic leukemia. PML-RARA driven pathogenesis and the molecular basis for therapy response have been the focus of many studies, which have now converged into an integrated physio-pathological model. The latter is well supported by clinical and molecular studies on patients, making APL one of the rare hematological disorder cured by targeted therapies. Here we review recent data on APL-like diseases not driven by the PML-RARA fusion and discuss these in view of current understanding of “classic” APL pathogenesis and therapy response.

The RASopathies are a group of genetic syndromes caused by upregulated RAS signaling. Noonan syndrome (NS), the most common entity among the RASopathies, is characterized mainly by short stature, cardiac anomalies and distinctive facial features. Mutations in multiple RAS-MAPK pathway-related genes have been associated with NS and related phenotypes. We describe two unrelated patients presenting with hypertrophic cardiomyopathy (HCM) and dysmorphic features suggestive of NS. One of them died in the neonatal period because of cardiac failure. Targeted sequencing revealed de novo MRAS variants, c.203C > T (p.Thr68Ile) and c.67G > C (p.Gly23Arg) as causative events. MRAS has only recently been related to NS based on the observation of two unrelated affected individuals with de novo variants involving the same codons here found mutated. Gly23 and Thr68 are highly conserved residues, and the corresponding codons are known hotspots for RASopathy-associated mutations in other RAS proteins. Functional analyses documented high level of activation of MRAS mutants due to impaired GTPase activity, which was associated with constitutive plasma membrane targeting, prolonged localization in non-raft microdomains, enhanced binding to PPP1CB and SHOC2 protein, and variably increased MAPK and PI3K-AKT activation. This report provides additional evidence that a narrow spectrum of activating mutations in MRAS represents another rare cause of NS, and that MRAS has to be counted among the RASopathy genes predisposing to HCM. Moreover, our findings further emphasize the relevance of the MRAS-SHOC2-PPP1CB axis in the control of MAPK signaling, and the contribution of both MAPK and PI3K-AKT pathways in MRAS functional upregulation.

Abstract Social media platforms have become fundamental tools for sharing information during natural disasters or catastrophic events. This paper presents SEDOM-DD (Sub-Events Detection on sOcial Media During Disasters), a new method that analyzes user posts to discover sub-events that occurred after a disaster (e.g., collapsed buildings, broken gas pipes, floods). SEDOM-DD has been evaluated with datasets of different sizes that contain real posts from social media related to different natural disasters (e.g., earthquakes, floods and hurricanes). Starting from such data, we generated synthetic datasets with different features, such as different percentages of relevant posts and/or geotagged posts. Experiments performed on both real and synthetic datasets showed that SEDOM-DD is able to identify sub-events with high accuracy. For example, with a percentage of relevant posts of 80% and geotagged posts of 15%, our method detects the sub-events and their areas with an accuracy of 85%, revealing the high accuracy and effectiveness of the proposed approach.